The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Journal Information
Full Title: Ann Hematol
Abbreviation: Ann Hematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateData on patients were retrospectively collected by the 1975 guidelines of the Declaration of Helsinki. The research was approved by the Ethical Committee of Cagliari (PROT. PG/2014/21960). Conflict of interestProf. Massimo Breccia is Editor of Annals of Hematology. The other authors have no disclosures to declare. Conflict of interest Prof. Massimo Breccia is Editor of Annals of Hematology. The other authors have no disclosures to declare."
"Funding Open access funding provided by Università degli Studi di Cagliari within the CRUI-CARE Agreement."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025